A Single-Center, Multiple-Dose, Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study to Investigate the Effect of Balovaptan on the QTC Interval in Healthy Subjects
Latest Information Update: 27 Jul 2020
Price :
$35 *
At a glance
- Drugs Balovaptan (Primary) ; Moxifloxacin
- Indications Autistic disorder
- Focus Therapeutic Use
- Sponsors Roche
- 23 Jul 2019 Status changed from active, no longer recruiting to completed.
- 22 Apr 2019 Status changed from recruiting to active, no longer recruiting.
- 24 Jan 2019 New trial record